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11. EXECUTIVE SUMMARY
Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is 
highly endemic in some regions of North America, Central America, and South America and 
is also reported in certain countries of Asia and Africa. It often affects people with impaired 
immunity, including people living with HIV, among whom the most frequent clinical presentation 
is disseminated histoplasmosis. The symptoms of disseminated histoplasmosis are non-specific 
and may be indistinguishable from those of other infectious diseases, especially disseminated 
tuberculosis (TB), thus complicating diagnosis and treatment. Histoplasmosis is one of the most 
frequent opportunistic infections caused by fungal pathogens among people living with HIV in the 
Americas and may be responsible for 5–15% of AIDS-related deaths every year in this Region.
These guidelines aim to provide recommendations for the diagnosis, treatment, and management 
of disseminated histoplasmosis in persons living with HIV. Although the burden of disease is 
concentrated in the Americas, the recommendations contained within these guidelines are 
applicable globally. These guidelines were produced in accordance with the World Health 
Organization (WHO) handbook for guideline development. The Guideline Development Group 
elaborated the final recommendations based on systematic review of scientific literature and 
critical evaluation of the evidence available using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) approach.
These guidelines are intended for health-care providers, HIV program managers, policy-makers, 
national treatment advisory boards, and other professionals involved in caring for people who 
either have or may be at risk of developing disseminated histoplasmosis.
2Recommendations
1. Diagnosis of disseminated histoplasmosis among people living with HIV: Among 
people living with HIV, disseminated histoplasmosis should be diagnosed by detecting 
circulating Histoplasma antigens (conditional recommendation; low-certainty evidence).
2. Induction and maintenance of antifungal treatment regimens for disseminated 
histoplasmosis among people living with HIV
Disseminated histoplasmosis classification definitions
• Severe or moderately severe histoplasmosis is defined as the presence of at least one 
sign or symptom involving vital organs: respiratory or circulatory failure, neurological 
signs, renal failure, coagulation anomalies and a general alteration of the WHO 
performance status greater than 2, in which the person is confined to a bed or chair more 
than half of the waking hours and only capable of limited self-care.
• Mild to moderate histoplasmosis is defined as signs and symptoms that do not include 
the above features defining severe or moderately severe histoplasmosis. 
2.1 Induction therapy
2.1.1 Treating severe or moderately severe histoplasmosis among people living with 
HIV: liposomal amphotericin B, 3.0 mg/kg, for two weeks is recommended (conditional 
recommendation; very-low-certainty evidence).
In settings where liposomal amphotericin B is unavailable, deoxycholate amphotericin B, 0.7–
1.0 mg/kg, is recommended for two weeks (conditional recommendation; very-low-certainty 
evidence). As a good practice for people with renal failure, or at risk of renal injury, measures 
to prevent or treat toxicity are recommended (subsection 3.5).
Induction therapy should be given for two weeks. Since deoxycholate amphotericin B may 
be associated with renal toxicity, therapy may need to be shorter than two weeks based on 
the clinical assessment of how the person responds to treatment. Involvement of the central 
nervous system may require extending induction therapy or increasing dosage. 
2.1.2 Treating mild to moderate histoplasmosis among people living with HIV: itraconazole 200 
mg three times daily for three days and then 200 mg twice daily is recommended (conditional 
recommendation, very-low-certainty evidence).
2.2 Maintenance therapy: itraconazole 200 mg twice daily for 12 months is recommended 
(conditional recommendation; very-low-certainty evidence). Less than 12 months of therapy 
can be considered when the person is clinically stable, receiving antiretroviral therapy, has 
suppressed viral load, and the immune status has improved (conditional recommendation, 
very-low-certainty evidence).
3. Timing of antiretroviral therapy initiation: antiretroviral therapy should be initiated as 
soon as possible among people with disseminated histoplasmosis for whom central nervous 
system involvement is not suspected or proven (conditional recommendation; very-low-
certainty evidence).
4. TB therapy for people coinfected with TB, HIV, and histoplasmosis: People living 
with HIV with TB and histoplasmosis coinfection should receive TB therapy according to WHO 
treatment guidelines (conditional recommendation; very-low-certainty evidence) 
32. BACKGROUND
Considerable progress has been made in access to HIV testing and treatment globally, with 79% 
of people living with HIV aware of their status and 62% receiving treatment in 2018. Expanding the 
testing and treatment of HIV has led to a decline in HIV-associated mortality globally by 33% between 
2010 and 2018. Nevertheless, an estimated 770,000 people died from HIV-related illness in 2018 (1). 
Global progress has been mirrored in Latin America and the Caribbean, where an estimated 79% 
of people living with HIV knew their status and 61% were receiving treatment in 2018. Despite this 
progress, the number of people dying from HIV-associated causes declined by only 19% from 2010 
to 2018 (41,000 in 2018). Further, more than 30% of the people newly diagnosed with HIV in Latin 
America and the Caribbean present to care with advanced HIV disease (initial CD4 cell count less 
than 200 cells/mm³), with little to no progress compared with 2016 (1). For Latin America and the 
Caribbean to reach the regional target of fewer than 19,000 people dying annually from HIV-related 
causes, national programs need to enhance their capacity to diagnose HIV earlier, offer antiretroviral 
therapy with rapid initiation to everyone living with HIV regardless of their immune status and 
address the most common causes of illness and death among people living with HIV (2).
Globally, leading causes of mortality among adults with advanced HIV disease include tuberculosis 
(TB), severe bacterial infections, cryptococcal meningitis, toxoplasmosis, and Pneumocystis jirovecii 
pneumonia. Among children, TB, severe bacterial infections, Pneumocystis jirovecii pneumonia, 
diarrheal diseases, malnutrition, and wasting are the leading causes of death (3). In Latin America and 
the Caribbean, in addition to TB (2), fungal infections are a major contributor to mortality, especially 
histoplasmosis, cryptococcal meningitis, and Pneumocystis jirovecii pneumonia; recent estimates 
suggest that the burden of histoplasmosis is equivalent in incidence and even higher in deaths 
compared with TB among people living with HIV in Latin America (4–6).
Histoplasmosis has a high endemicity in certain areas of the Americas (7). Although most frequently 
diagnosed in the Americas, it is also diagnosed in certain countries of Asia (China, India, Indonesia, 
Japan, Malaysia, Singapore, Thailand, and Viet Nam) and Africa (Central African Republic, Congo, Côte 
d’Ivoire, Democratic Republic of the Congo, Gambia, Guinea Bissau, Liberia, Senegal, South Africa, and 
Uganda) (8). Among people living with HIV, the most frequent clinical presentation of this disease is 
disseminated histoplasmosis. Symptoms of disseminated histoplasmosis are nonspecific and may be 
indistinguishable from those of other infectious diseases, especially TB, thus complicating diagnosis 
and treatment (9). Most histoplasmosis reports come from the Region of the Americas, and each year 
there are up to 15,600 new cases and 4,500 deaths among people living with HIV (4).
Although recent technological advances have improved the diagnostic accuracy of fungal diseases, 
these technologies are not yet widely available. Conventional laboratory methods such as culture and 
histopathology that are used for diagnosing histoplasmosis have several limitations; these include the 
need for complex laboratory infrastructure (Biosafety Level 3 laboratory), limited laboratory staff with 
mycology training, delays of several weeks for final diagnosis, and variable diagnostic sensitivity (10). 
Antibody tests are less sensitive for immunocompromised people, with sensitivity ranging between 
38% and 70%, and not usually helpful for diagnosing disseminated histoplasmosis among people 
living with HIV (10). Although the detection of circulating Histoplasma antigens in urine by enzyme-
linked immunosorbent assay (ELISA) has proven highly sensitive (95%) for diagnosing disseminated 
histoplasmosis, testing is hampered by the limited availability of commercial in vitro diagnostic kits 
and poor local distribution (10). In summary, lack of access to appropriate antifungal therapies, in 
vitro diagnostics for rapid detection of histoplasmosis and the co-occurrence of other infectious 
4diseases, especially TB, may affect clinical outcomes and underlie the high mortality of disseminated 
histoplasmosis among people living with HIV (11, 12).
Recognizing the importance of addressing late HIV diagnosis and deploying differentiated packages 
of care for people living with HIV with advanced HIV disease, the WHO has recently published 
guidance documents and recommendations for managing advanced HIV disease and rapidly 
initiating antiretroviral therapy (3) and updated guidelines for diagnosing, preventing, and 
managing cryptococcal disease among  adults, adolescents, and children living with HIV (13). WHO’s 
consolidated guidelines for managing advanced HIV disease do not include histoplasmosis but 
acknowledge its higher burden in Latin America. In 2019, WHO’s updated Model List of Essential 
In Vitro Diagnostics included Histoplasma antigen testing, and the List of Essential Medicines 
included new effective antifungal agents (14, 15). Guidelines for managing advanced HIV disease 
were developed before the availability and inclusion of Histoplasma antigen assays and antifungal 
medicines in the WHO Model List of Essential In Vitro Diagnostics. These new opportunities, 
together with updated data on the burden of histoplasmosis among people living with HIV, 
provide the rationale for producing this WHO guidance for diagnosing and managing disseminated 
histoplasmosis among people living with HIV.
2.1 Objectives
The objectives of these guidelines are to provide updated, evidence-informed recommendations as 
well as additional clinical and implementation guidance for a public health approach to diagnosing 
and managing disseminated histoplasmosis and disseminated histoplasmosis and TB coinfection 
among people living with HIV. The recommendations contained in these guidelines and provision of 
technical cooperation for their implementation is expected to improve the capacity to diagnose and 
treat histoplasmosis throughout regions that are endemic for this disease.
2.2 Target audience
The target audience for these guidelines includes HIV program managers, policy-makers, national 
treatment advisory boards, implementing partners, and health-care professionals providing care 
for people living with HIV in resource-limited settings, especially in countries with a high burden 
of histoplasmosis. These guidelines were initially developed for Latin America and the Caribbean. 
Nevertheless, the recommendations apply globally.
2.3 Guiding principles
The following principles have informed the development of these guidelines:
• The guidelines are based on a public health approach to scaling up the use of antiretroviral 
therapy  along the continuum of HIV prevention, care, and treatment.
• Detecting HIV infection early and rapidly initiating antiretroviral therapy, regardless of CD4 
count or immune status (“treat all”), are the most important strategies to reduce the incidence 
of opportunistic infections.
5• Early and rapid diagnosis and prompt initiation of optimal antifungal treatment are essential 
to improving survival among people living with HIV who have histoplasmosis.
• People should be promptly referred for HIV testing and care after being diagnosed with 
histoplasmosis to facilitate prompt HIV diagnosis, linkage to care and uptake of antiretroviral 
therapy.
The implementation of the recommendations in these guidelines should be informed by local 
context, including HIV epidemiology, the burden of histoplasmosis, the prevalence of other 
comorbidities, access to laboratory services and availability of specific assays, access to antifungal 
medicines for treatment, the organization and capacity of the health system, and the anticipated 
cost-effectiveness.
Annex 1 summarizes the methods for developing these guidelines.
63.  KEY RECOMMENDATIONS, RATIONALE,  
AND EVIDENCE SUMMARY
3.1  Diagnosis of disseminated histoplasmosis 
among people living with HIV
Disseminated histoplasmosis should be diagnosed among people living with HIV by  
detecting circulating Histoplasma antigens (conditional recommendation; low-certainty 
evidence). 
3.1.1 Background and rationale
The traditional gold standard for diagnosing histoplasmosis is based on conventional laboratory 
tests (culture, histopathology, and special stains) (10, 16). However, these assays have important 
limitations, notably the need for laboratory infrastructure for handling isolates (Biosafety Level 3), the 
need for laboratory staff with appropriate training and experience, variable analytical performance 
of the tests and long turnaround time for diagnosis. Several weeks are required to undertake fungal 
culture, and this can lead to providing empirical treatment while awaiting the results, potentially 
adding unnecessary toxicity and associated costs to patient care (10, 16). Alternatively, people may 
die if treatment is delayed while awaiting culture confirmation (17). The Guideline Development 
Group was confident that this recommendation can be achieved in most countries, although 
financial and technical support may be needed in some settings to strengthen laboratory capacity 
to be able to provide adequate and timely testing. The Guideline Development Group also noted the 
need to strengthen implementation strategies (for example, educational programs) to improve the 
diagnosis of histoplasmosis (18) (Annex 2).
3.1.2 Systematic review
A systematic review and a meta-analysis compared the diagnostic accuracy of different laboratory 
approaches for disseminated histoplasmosis among people living with HIV (19). Studies were 
included for analysis if they demonstrated validation of Histoplasma laboratory assays among 
people living with HIV using culture or histopathological analysis to determine proven cases as 
defined by the European Organization for Research and Treatment of Cancer/Invasive Fungal 
Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group Consensus Group (20). Meta-analysis found that antigen detection tests have the 
highest analytical performance for diagnosing disseminated histoplasmosis among people living 
with HIV (overall sensitivity 95% and specificity 97%). Culture-based assays presented variable 
analytical performance in diagnosing disseminated histoplasmosis (overall sensitivity of 77% and 
unknown specificity). Antibody testing had high specificity but low sensitivity, probably because 
these people are highly immunosuppressed. Molecular testing through DNA detection showed high 
7diagnostic accuracy (sensitivity 95% and specificity 99%), but the lack of consensus on techniques 
or procedures and the lack of availability of commercial kits makes implementing these types of 
assays difficult (19) (Annex 3).
Antigen detection assays were the most accurate method for diagnosing disseminated 
histoplasmosis among people living with HIV. These types of assays are commercially available as 
kits, which facilitates transfer of this assay to clinical laboratories. Using commercial assays reduces 
technical problems related to reproducibility and permits to undertake a better quality control. In 
addition, antigen testing can be performed in laboratories with lower level biosecurity (Biosafety 
Level 1 and 2 laboratories). In settings where Histoplasma antigen testing has been implemented, 
the number of diagnosed cases increased significantly, providing further evidence of the higher 
analytical performance of this type of assay (17, 18, 21, 22). In addition, the relative ease and 
speed with which these antigen assays can be performed and the use of non-invasive samples 
has reduced the time to diagnosis and the mortality associated with disseminated histoplasmosis 
among people living with HIV (17, 18, 21, 22). The main limitation is that commercial kits are only 
available in ELISA format, and point-of-care testing is needed to further reduce diagnostic delays. 
Further, assay distribution and costs need to be evaluated in each setting. Annex 4 summarizes the 
alternative commercially available assays for diagnosing histoplasmosis.
3.1.3 Recommendation
The Guideline Development Group recommends antigen detection assays to diagnose disseminated 
histoplasmosis among people living with HIV. This recommendation is based on the high diagnostic 
accuracy of Histoplasma antigen testing for these people and is also supported by preference 
for non-invasive testing and ease of use in resource-limited settings. The recommendation is 
conditional, since it is based on low-certainty evidence.
This recommendation applies to suspected disseminated histoplasmosis among people living 
with HIV. In the case of mucocutaneous infections, central nervous system, and pulmonary-only 
localizations of histoplasmosis may require complementary testing such as serum antibody tests or 
culture and histopathological analysis of different specimens, including tissue biopsy or body fluids.
83.2  Induction and maintenance antifungal 
treatment regimens for disseminated 
histoplasmosis among people living with HIV
3.2.1 Disseminated histoplasmosis classification definitions
The categories of disseminated histoplasmosis are defined as follows:
• Severe or moderately severe histoplasmosis is defined as the presence of at least one sign 
or symptom involving vital organs: respiratory or circulatory failure, neurological signs, renal 
failure, coagulation anomalies and a general alteration of the WHO performance status greater 
than 2, in which the person is confined to a bed or chair more than half of the waking hours 
and only capable of limited self-care.
• Mild to moderate histoplasmosis is defined as signs and symptoms that do not include the 
above features defining severity.
3.2.2 Induction therapy
Treating severe or moderately severe histoplasmosis among people living with HIV: 
liposomal amphotericin B, 3.0 mg/kg, for two weeks is recommended (conditional 
recommendation; very-low-certainty evidence).
Treating mild to moderate histoplasmosis among people living with HIV: itraconazole 
200 mg three times daily for three days and then 200 mg twice daily is recommended 
(conditional recommendation, very-low-certainty evidence).
3.2.2.1 Background and rationale
Disseminated histoplasmosis among people living with HIV is a rapidly progressing, life-threatening 
infection that requires prompt treatment with antifungal medication. The standard treatment, 
deoxycholate amphotericin B has good treatment success rates (23) but is associated with 
considerable toxicity, especially infusion-related toxicity, renal failure, electrolyte abnormalities, and 
anemia (24, 25). The Guideline Development Group considered that not all regimens for treating 
moderate or severe disseminated histoplasmosis are consistently available in all resource-limited 
settings. The Guideline Development Group further recognized that there may be concerns about 
adverse events associated with some of the proposed treatments but was confident that the 
treatments recommended offer improved safety and tolerability compared with the alternatives; as 
such, the Guideline Development Group considered that the values and preferences overall favored 
the proposed interventions. In addition, the Guideline Development Group noted that therapeutic 
drug monitoring is proposed in some settings; however, the feasibility of implementing therapeutic 
drug monitoring and some treatment options depends on resource availability (26). However, the 
absence of therapeutic drug monitoring or of the first-line recommended treatment should not 
9be a reason to not give treatment for disseminated histoplasmosis, a potentially fatal disease. 
Acceptability of treatment is a key issue because suboptimal adherence to using an antifungal 
drug is associated with treatment relapse and mortality among people living with HIV who have 
disseminated histoplasmosis (27, 28). The Guideline Development Group was confident that key 
stakeholders are likely to find this recommendation acceptable (Annex 2).
3.2.2.2 Systematic review
The systematic review identified four studies, including one randomized trial, that compared the efficacy 
of liposomal amphotericin B versus deoxycholate amphotericin B for induction therapy for moderately 
severe to severe disseminated histoplasmosis among people living with HIV (Annex 5). Compared with 
deoxycholate amphotericin B, the people treated with liposomal amphotericin B had improved clinical 
success (82% versus 56%), lower mortality (2% versus 13%) and less nephrotoxicity (9% versus 
37%) (24, 29).
For treating people with less severe disease, fluconazole (800 mg daily for 12 weeks) was less 
effective than itraconazole (200 mg three times a day for three days and then 200 mg twice daily 
for 12 weeks) (30, 31). Moreover, triazoles all showed lower efficacy than polyenes among more 
severely ill people. Randomized trials of amphotericin B formulations compared with triazole 
antifungal agents have not been conducted (32).
3.2.2.3 Recommendations
Treating severe or moderately severe histoplasmosis among people living with HIV
Liposomal amphotericin B, 3.0 mg/kg for two weeks is recommended as the preferred treatment. 
This recommendation is conditional based on the very-low-certainty evidence (Annex 2).
Induction therapy should be given for two weeks. Because amphotericin B is associated with renal 
toxicity, the duration of therapy can be shortened based on clinical assessment of how the person 
responds to treatment.
Involvement of the central nervous system may require extending induction therapy or increasing 
dosage.
Alternative treatment for severe or moderately severe histoplasmosis among people 
living with HIV
In resource-limited settings where liposomal amphotericin B is unavailable, deoxycholate 
amphotericin B (0.7–1.0 mg/kg) should be administered for the initial two weeks. This is a 
conditional recommendation, based on very-low-certainty evidence because of imprecision and 
indirectness. For people with renal failure or at risk of renal injury, preventing and monitoring 
toxicity associated with deoxycholate amphotericin B are recommended (13).
Treating mild to moderate histoplasmosis among people living with HIV
Itraconazole 200 mg twice daily after a loading dose of 200 mg three times daily for three days 
is recommended. This is a conditional recommendation, based on very low certainty of evidence, 
because of imprecision and indirectness.
Based on the histoplasmosis treatment guidelines of the Infectious Diseases Society of America, 
this recommendation can be used for treating HIV-uninfected immunosuppressed individuals for 
disseminated histoplasmosis (25).
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3.2.3 Maintenance therapy
Itraconazole 200 mg twice daily for 12 months is recommended (conditional 
recommendation; very-low-certainty evidence). Less than 12 months of therapy can 
be considered when the person is clinically stable, receiving antiretroviral therapy, has 
suppressed viral loads, and the immune status has improved (conditional recommendation, 
very-low-certainty evidence).
3.2.3.1 Background and rationale
After successful induction therapy for disseminated histoplasmosis among people living with HIV, 
rates of relapse can be as high as 90% among people not receiving maintenance therapy (32). 
Relapse occurs more frequently 6–18 months after discontinuing induction therapy. Reinfection can 
occur in regions that are hyperendemic for histoplasmosis (23). Antifungal maintenance therapy is 
therefore necessary to effectively suppress residual infection and prevent relapse. Treatment success 
rates are higher when maintenance therapy is with itraconazole (75%) compared with fluconazole 
(40%) (33, 34), although direct randomized comparisons are lacking. Itraconazole treatment 
200 mg twice daily is usually preceded by a loading dose of 200 mg itraconazole thrice daily for 
three days to achieve steady-state itraconazole concentrations more rapidly (35). The efficacy and 
duration of such regimens required for people with central nervous system involvement is less clear.
The ideal duration of maintenance therapy has not been established and should be determined 
based on clinical judgment. Lifelong maintenance antifungal therapy has been recommended in 
some national guidelines, and relapses were usually associated with poor adherence to therapy, 
low itraconazole levels or central nervous system infection. Guidelines from the Infectious Diseases 
Society of America recommend maintenance therapy with azoles for one year (25).
3.2.3.2 Systematic review
The systematic review sought to compare the efficacy and safety of maintenance therapy with 
12 months of oral itraconazole with shorter durations of maintenance therapy. The only study to 
report evidence on this comparison was a retrospective cohort study that compared a group in 
which maintenance therapy was discontinued (38 participants) with a group in which maintenance 
therapy was continued (59 participants) (28). The review authors judged the study to be at high risk 
of bias (29).
3.2.3.3 Recommendation
Itraconazole (200 mg twice daily) for one year is the recommended maintenance therapy. The 
recommendation is conditional, with very-low-certainty evidence because of imprecision and 
indirectness. The Guideline Development Group decided that the desirable effects of shortening the 
maintenance course were moderate and undesirable effects were trivial; there was no important 
uncertainty of values. The balance of effects was therefore judged to be in favor of the intervention, 
which was both feasible and acceptable. Itraconazole and dolutegravir, antiretroviral drug used in 
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combination with two nucleoside reverse-transcriptase inhibitors for WHO-recommended first-line 
regimens, have no expected drug–drug interactions. Annex 7 presents more information on drug–
drug interactions between itraconazole and antiretroviral drugs. The University of Liverpool’s drug 
interaction charts may also be consulted online at https://www.hiv-druginteractions.org (36).
Balancing the risk of relapse, drug–drug interactions, and side-effects, clinicians may opt for shorter 
courses (at least six months long) of maintenance therapy. The Guideline Development Group 
is aware that short maintenance therapy (3–6 months) has been used successfully for people 
receiving antiretroviral therapy, with suppressed viral loads, and clinically stable with immune 
recovery. Shortening the duration should be based on how the person responds to antiretroviral 
therapy with an undetectable viral load, some immune recovery, which can be defined as CD4 cell 
counts >200 cells/mm3, and clinical resolution of histoplasmosis. People with drug–drug interactions 
are more likely to benefit from shorter courses of maintenance therapy (28, 37). This conditional 
shortening of maintenance therapy was judged to be aligned with the values and preferences of 
people with disseminated histoplasmosis, physicians, and policy-makers (Annex 2). The Guideline 
Development Group recommendation for shortening maintenance therapy is conditional, with very-
low-certainty evidence because of imprecision and indirectness.
Based on the histoplasmosis treatment guidelines of the Infectious Diseases Society of America, 
this recommendation can be used for treating HIV-uninfected immunosuppressed individuals for 
disseminated histoplasmosis (25).
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3.3 Timing of antiretroviral therapy initiation
Antiretroviral therapy should be initiated as soon as possible among people with 
disseminated histoplasmosis for whom central nervous system involvement is not 
suspected or proven (conditional recommendation; very-low-certainty evidence).
3.3.1 Background and rationale
WHO guidelines recommend initiating antiretroviral therapy within seven days after HIV diagnosis 
and that people with advanced HIV disease be given priority for assessment and antiretroviral 
therapy initiation; these guidelines further recommend that antiretroviral therapy initiation should 
be offered on the same day to people who are ready to start (3). However, people presenting for 
the first time or those returning to care should undergo evaluation for opportunistic infections, 
in particular signs and symptoms of TB and cryptococcal meningitis, before antiretroviral therapy 
initiation is offered. Immediate antiretroviral therapy initiation is contraindicated among people 
living with HIV who have cryptococcal meningitis because of the increased mortality presumed 
to be caused by immune reconstitution inflammatory syndrome in the central nervous system, 
especially in the context of increased intracranial pressure (13, 3). Apart from the above situation, 
evidence indicates that starting antiretroviral therapy within 14 days of starting treatment for acute 
opportunistic infections (Pneumocystis jirovecii pneumonia, cryptococcal meningitis, and bacterial 
infections) reduced disease progression and death in individuals with other opportunistic infections 
(38) (Annex 2).
3.3.2 Systematic review
The systematic review sought to compare the outcomes of early versus delayed initiation of 
antiretroviral therapy. One randomized clinical trial with 282 participants met the inclusion criteria 
(39). Only 10 participants had HIV and a presumptive or confirmed diagnosis of disseminated 
histoplasmosis. By day 30, one of the seven people in the early arm and none of the three people in 
the late arm died. Based on this limited evidence, the efficacy and safety outcomes of early versus 
late initiation of antiretroviral therapy are unknown (29).
3.3.3 Recommendation
Antiretroviral therapy should not be delayed for people diagnosed with disseminated 
histoplasmosis who are administered antifungal therapy. The recommendation is conditional 
with very-low-certainty evidence. The Guideline Development Group considered that the risk of 
potential harms was minor. The recommendation was judged feasible and likely to be acceptable, 
with possible important uncertainty regarding values and preferences and the balance of effects. 
This recommendation is based on the balance between the substantial risk of dying from another 
opportunistic infection when delaying antiretroviral therapy and the low incidence of immune 
reconstitution inflammatory syndrome versus morbidity and mortality associated with immune 
reconstitution inflammatory syndrome among people living with HIV receiving antiretroviral therapy 
who have histoplasmosis. Immune reconstitution inflammatory syndrome appears to be uncommon 
among people with disseminated histoplasmosis following antiretroviral therapy initiation (38). 
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Most of the literature on immune reconstitution inflammatory syndrome is case reports or small 
case series, which cannot provide evidence on the incidence of immune reconstitution inflammatory 
syndrome or the optimal timing of antiretroviral therapy (Annex 2).
This recommendation regarding the timing of antiretroviral therapy only applies to people without 
central nervous system involvement, to avoid immune reconstitution syndrome in the central 
nervous system.
3.3.4  Managing immune response inflammatory syndrome 
associated with histoplasmosis
Immune reconstitution inflammatory syndrome associated with histoplasmosis is unusual, occurring 
at about 0.74 cases per 1,000 person-years among people living with HIV (38). Typically, immune 
reconstitution inflammatory syndrome occurs a median of 60 days after initiating antiretroviral 
therapy. The features of histoplasmosis-associated immune reconstitution inflammatory syndrome 
are non-specific and resemble disseminated histoplasmosis, with symptoms including fever, 
weight loss, cough, diarrhea and abdominal pain. Typically, antifungal therapy does not need to be 
adjusted. The following steps are recommended for managing immune reconstitution inflammatory 
syndrome associated with histoplasmosis:
• continue antiretroviral therapy; and
• ensure optimal antifungal therapy.
Short-course oral steroid therapy can be considered if there are life-threatening complications 
despite appropriate treatment of histoplasmosis. In these cases, it has been recommended that 1–2 
mg/kg per day of prednisone or the equivalent be given for 1–2 weeks followed by dose-tapering 
for two weeks.
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3.4  TB therapy for people coinfected with TB, HIV, 
and histoplasmosis
People living with HIV with TB and histoplasmosis coinfection should receive TB therapy 
according to WHO treatment guidelines (conditional recommendation; very-low-certainty 
evidence) .
3.4.1 Background and rationale
TB and histoplasmosis coinfection is a challenge because the symptoms are non-specific. 
Coinfection is frequent although likely underestimated, since clinicians may stop investigation 
after initial diagnosis and thus fail to see coinfections. Depending on the local epidemiology, this 
situation may occur frequently among people living with HIV (8–38%), and screening should 
look for both diagnoses (12). When coinfections are diagnosed, this can lead to complex patient 
management, with drug–drug interactions that may affect HIV, TB, and histoplasmosis treatment. 
In particular, rifampicin results in reduced itraconazole levels, potentially leading to ineffective 
treatment for histoplasmosis (40) (Annex 6).
3.4.2 Systematic review
To address this concern, a systematic review was conducted to assess whether TB therapy should 
be adjusted for people coinfected with TB and histoplasmosis. This review found only two studies 
(including one case report) reporting on treatment outcomes among coinfected people (40, 41). The 
rationale for this recommendation therefore relies on the expertise of the Guideline Development 
Group and considers existing guidance on managing HIV and TB coinfection (Annex 2).
3.4.3 Recommendation
People living with HIV with TB and histoplasmosis coinfection should receive prompt treatment 
after diagnosis according to WHO treatment guidelines. The recommendation balances the risk for 
M. tuberculosis resistance and the risk of drug–drug interactions (rifampicin and itraconazole), 
leading to subtherapeutic itraconazole levels and potential ineffective treatment for histoplasmosis. 
The Guideline Development Group judged that there may be important variability in how much the 
people with histoplasmosis, physicians, and policy-makers value the main outcome but that the 
intervention was feasible and acceptable (Annex 2).
This recommendation has several possible resource implications. It is important to review potential 
antiretroviral therapy options for people with coinfection and to make necessary adjustments as 
recommended in WHO’s consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection. Because of the potential decrease in itraconazole levels related to some 
types of antiretroviral therapy, itraconazole drug levels should be monitored if possible (42). When 
histoplasmosis is not controlled because of interactions with rifampicin and itraconazole, clinicians 
may consider, depending on local context, extending the duration of amphotericin B induction 
therapy, once-weekly courses of amphotericin B, increasing the itraconazole dose and monitoring 
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the blood level and toxicity and considering using other azole drugs (posaconazole, voriconazole, or 
fluconazole). Finally, clinicians can consider replacing rifampicin with rifabutin.
Treatment may need to be revised for people experiencing toxicity, drug-drug interactions, or for 
those with resistance profiles requiring protease inhibitors or second-line anti-TB drugs. When 
possible, antiretroviral resistance genotyping and M. tuberculosis drug susceptibility testing may 
assist clinical decisions. Itraconazole serum level testing may not be available in some areas.
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3.5  Preventing, monitoring, and managing 
histoplasmosis among people living with HIV
3.5.1  Monitoring the toxicity of amphotericin B treatment
• Drug toxicity and side-effects from amphotericin B therapy and drug–drug 
interactions associated with itraconazole use are important barriers to the 
successful treatment of people living with HIV who have histoplasmosis, especially 
in low- and middle-income countries (Annex 5).
• Safe administration of amphotericin B formulations is a priority and may require 
referral to a center with resources available to manage toxicity.
• Renal function should be evaluated to prevent, monitor, and manage toxicity such as 
nephrotoxicity, hypokalemia, infusion-related reactions and anemia.
• Renal function should be measured to reduce the risk of kidney damage, including 
appropriate fluid and electrolyte reposition, in addition to drug infusion (for 
deoxycholate amphotericin B) over 4–6 hours (43).
3.5.1.1 Background and rationale
Adverse effects of amphotericin B therapy include renal toxicity, anemia, hypokalemia, 
hypomagnesemia and acute infusion-related reactions. A review of using amphotericin 
B formulations for treating people living with HIV for histoplasmosis found that 
nephrotoxicity was common (18%), as was infusion-related toxicity (36%) (24). In a 
study from Uganda among people with cryptococcal meningitis, proactive fluid and 
electrolyte management as part of amphotericin-based therapy was associated with 
improved survival (44).
The most common adverse reactions associated with itraconazole for treating people 
with histoplasmosis are nausea and vomiting, rash and pedal edema (31, 45). An 
important limitation to using itraconazole is variable bioavailability, and the guidelines 
of the Infectious Diseases Society of America recommend monitoring serum itraconazole 
levels for disseminated histoplasmosis (25). Serum concentrations are useful for 
determining whether itraconazole is adequately absorbed and may also be helpful 
in assessing adherence and the impact of drug–drug interactions. Toxicity has been 
associated with higher serum levels of itraconazole among people with aspergillosis (46).
3.5.2 Monitoring the treatment response
• Clinical response, including resolution of fever, fatigue, and weight changes and 
other symptoms associated with disease severity (hypotension and hypoxia) should 
be assessed daily during the initial period of induction therapy (13).
• Itraconazole blood levels, where available, should be monitored after two weeks 
of therapy. Blood levels of itraconazole between 1 and 2 μg/mL have been 
recognized as effective. Concentrations higher than 15 μg/mL has been related with 
development of toxic (42). Lack of capacity for drug monitoring should not be an 
obstacle to itraconazole treatment.
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• The co-occurrence of other opportunistic infections should be evaluated by clinical evaluation 
and using specific laboratory testing for other opportunistic infections (12, 47).
3.5.3 Diagnostic approach to persistent or recurrent symptoms
About 25% of the people with disseminated histoplasmosis have persistent or recurrent symptoms. 
Persistent symptoms may be caused by failure of induction or maintenance therapy (inadequate 
dose or duration) or concomitant infection, such as TB (12, 24, 47). Recurrent symptoms, 
reappearing after symptoms initially resolve, may occur from inadequate doses of maintenance 
therapy (drug level and drug interactions), failure of adherence, other concomitant illness, and 
immune reconstitution inflammatory syndrome (25).
It is important to review treatment history to determine whether drug regimen, dosing, or duration 
of therapy have contributed to treatment failure. Adherence to therapy, itraconazole drug levels, 
and potential drug interactions should be investigated.
• Review patient adherence.
• Perform relevant investigations for other concomitant illnesses such as TB, especially among 
people with CD4 cells counts <200 cells/mm³.
• Consider paradoxical immune reconstitution inflammatory syndrome among people who have 
started antiretroviral therapy.
• Monitor progress by using Histoplasma antigen testing following treatment initiation (25, 48).
• Ensure appropriate drug levels, as necessary (42).
3.5.4 Managing relapse
In case of persistent or recurrent symptoms related to disseminated histoplasmosis, induction 
therapy should be restarted. It is important to ensure adherence to therapy and appropriate dose, 
drug levels, and duration.
Good practice statements
• Measure Histoplasma urinary antigen and perform other complementary laboratory tests, such 
as culture (25, 48).
• Restart induction or maintenance therapy (see subsection 3.2).
• Prevent, manage, and monitor for drug toxicity.
• Ensure appropriate drug levels, as necessary (42).  
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4. IMPLEMENTATION CONSIDERATIONS
Implementation challenges include: (1) access to rapid diagnostics; (2) access to optimal antifungal 
medicines; and (3) educating and training health-care providers.
4.1 Access to rapid diagnostics
Since early diagnosis and timely treatment initiation are key to improving mortality from 
histoplasmosis, countries need to give priority to access to high-quality in vitro diagnostics for rapid 
detection of Histoplasma antigen (17, 18, 21, 22). The WHO Model List of Essential In Vitro Diagnostics 
recently included immunoassays for Histoplasma antigen detection for implementation in clinical 
laboratory settings (14). Lateral flow assay–based rapid diagnostic tests for Histoplasma antigen 
will soon be available and provide additional opportunities to rapidly diagnose histoplasmosis at 
the point of care (49). Price negotiation and pooled procurement mechanisms should be used to 
improve access, especially for countries highly endemic for histoplasmosis. For Latin America and 
the Caribbean, the Pan American Health Organization (PAHO) Regional Revolving Fund for Strategic 
Public Health Supplies is one source of potential support. Implementing this recommendation implies 
taking appropriate steps to guarantee adequate availability of antigen testing in health facilities 
managing advanced HIV disease. Kit distribution and costs should be monitored to ensure that tests 
are accessible.
4.2 Access to optimal antifungal medicines
The WHO Model List of Essential Medicines (15) includes optimal antifungal medicines for treating 
people with histoplasmosis (conventional and liposomal amphotericin B and itraconazole). 
Nevertheless, these drugs are not widely available in many of the countries with a high burden of 
histoplasmosis, and the cost of treatment is extremely high, especially for liposomal amphotericin B. 
Barriers to accessing antifungal medications for treating histoplasmosis may be overcome by:
• increasing advocacy for drug price reduction, expanding the coverage of global access price 
initiatives, both in terms of scope (such as including histoplasmosis in the current access price of 
liposomal amphotericin B for leishmaniasis and cryptococcal meningitis) and eligible countries 
and promoting generic production, especially for amphotericin B;
• carrying out quality assurance of available generic formulations;
• ensuring national registration of all antifungal drugs and including them in national essential 
medicine lists based on the WHO Model List of Essential Medicines;
• procuring medicines through joint regional procurement mechanisms such as the PAHO Strategic 
Fund;
• ensuring adequate supply chains at the national level; and
• developing proper drug forecasting and monitoring systems.
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4.3 Educating and training health-care providers
Health-care providers need to have a low threshold for suspecting histoplasmosis among people 
living with HIV with advanced HIV disease and be trained in differential diagnoses with TB and other 
systemic fungal infections. Greater efforts need to be made to educate health-care providers and to 
provide policy guidance at the national level on managing histoplasmosis among people living with 
HIV. Effectively implementing guidelines also requires supportive supervision systems and prescribing 
decision-making aids.
4.4  Disseminating, adapting, and implementing the 
guidelines
These guidelines are available as a web-based product for dissemination and supported by 
peer-reviewed publications of the systematic reviews on which these recommendations are 
based. Although these guidelines were initially developed with a focus for the Americas, the 
recommendations in these guidelines apply globally, and as such will be integrated in the next edition 
of the WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV 
infection. These consolidated guidelines are planned to be reviewed and updated every 2–3 years.
WHO and PAHO will work closely with national health ministries and implementing partners to 
plan for rapidly disseminating, adapting, and implementing the recommendations. Key steps in 
dissemination include: presenting the recommendations at international conferences, workshops to 
support country adaptation, rapidly developing adaptation tools to assist countries in setting priorities 
among limited resources to facilitate full implementation over time, and carrying out briefings and 
joint planning for dissemination with international and national implementing partners. The policy 
uptake of the recommendations in national guidelines will be evaluated regularly.
4.5 Research needs
The following research questions emerge from the Guideline Development Group discussions and the 
evidence reviews:
• What is the antigen detection performance outside the context of advanced HIV disease?
• Among people with advanced HIV disease, can Histoplasma antigen detection be used as a 
screening approach for histoplasmosis?
• Can antigen detection performance be increased by designing new antibodies through significant 
support in developing basic science on Histoplasma capsulatum?
• Will a Histoplasma interferon-gamma release assay be useful to screen for latent histoplasmosis 
in advanced HIV disease, prevent histoplasmosis-associated immune reconstitution inflammatory 
syndrome and help to reduce the time to antiretroviral therapy initiation among people recently 
diagnosed with HIV?
• Can antigen detection screening studies inform about the true burden of histoplasmosis from a 
global perspective?
• Will recently developed Histoplasma antigen detection by lateral flow become the standard 
diagnostic method for disseminated histoplasmosis among hospitalized people with 
histoplasmosis, as an outpatient screening tool or both?
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• How can the specific impact of antigen detection on the incidence and mortality trends of HIV-
associated histoplasmosis be evaluated compared with conventional practices for diagnosing 
histoplasmosis and the future development of more molecular biology assays?
• What are the best definitions for severity of disease among people with histoplasmosis?
• Among people with a clinical and immune response to therapy, can maintenance antifungal 
therapy be safely discontinued earlier than 12 months?
• Do people with central nervous system involvement have a higher incidence of Histoplasma-
related immune reconstitution inflammatory syndrome and associated mortality? In relation to 
this, what is the optimal time to start antiretroviral therapy?
• When will Histoplasma antigen detection and liposomal amphotericin B be affordable to people 
with histoplasmosis in low- and middle-income countries?
• What are the outcomes of treating TB and histoplasmosis coinfection?
• What is the impact of genetic varieties of Histoplasma on the epidemiology and treatment 
response to histoplasmosis?
• What are the alternative antifungal drugs or alternative treatment stewardship in the pipeline 
that might help increase the efficacy and decrease the secondary effects and toxicity of the 
recommended therapy?
The optimal dose of liposomal amphotericin B has not been determined for people living with HIV 
who have disseminated histoplasmosis. Based on the experience with leishmaniasis, and more 
recently with cryptococcosis, high doses of liposomal amphotericin B given for short periods (including 
as a single dose) may work as well as standard (3 mg/kg) doses given for two weeks. A randomized 
multicenter Phase 2 clinical trial (NCT04059770) is planned to evaluate the activity of three regimens 
of liposomal amphotericin B in Brazil, for disseminated histoplasmosis in hospitalized adults living 
with HIV: (1) 10 mg/kg single dose; (2) 10 mg/kg on day one followed by 5 mg/kg on day three; 
and (3) 3 mg/kg for two weeks. All induction regimens will be followed by itraconazole at 400 mg/
day for one year. The study is estimated to be completed in October 2021. The incidence of immune 
reconstitution inflammatory syndrome should be quantified prospectively, and its severity should be 
described.
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ANNEX 1.  METHODS FOR DEVELOPING THE 
GUIDELINES
PAHO/WHO, advised by external experts, convened a guideline process to formulate guidelines on 
diagnosing and managing progressive disseminated histoplasmosis among people living with HIV. 
From May 2018 to October 2019, three groups worked to establish the key questions, analyze the 
evidence, and develop the guidance: (1) the WHO Steering Group, consisting of WHO experts; (2) 
the independent Guideline Development Group; and (3) the External Review Group. The Guideline 
Development Group and the External Review Group comprised experts with a wide variety of 
experience and knowledge in histoplasmosis and HIV. Gender, equity, human rights, and community 
perspectives were considered based on the expertise of the Guideline Development Group. The 
External Review Group members were sought from countries across WHO regions to ensure that diverse 
perspectives were included. The Guideline Development Group formulated all recommendations by using 
the GRADE approach.
Guideline Development Group meeting
The Guideline Development Group formulated guidelines on diagnosing and managing disseminated 
histoplasmosis among people living with HIV based on their knowledge of the optimal approach to 
diagnosing and managing histoplasmosis, using as reference the systemic reviews that were undertaken 
and considering the constraints of resource-limited settings. The Guideline Development Group had 
bi-monthly teleconferences between June 2018 and February 2019 and a face-to-face meeting in March 
2019. The systematic reviews and supportive evidence, including values and preferences, acceptability, 
feasibility, and cost, were presented to the Guideline Development Group. Evidence-to-decision-
making tables were prepared in accordance with the GRADE process and presented to the Guideline 
Development Group. A methodologist supported the formulation of the recommendations and facilitated 
discussions. The Guideline Development Group made decisions through a consensus process; all 
decisions were unanimous and voting was not required. Following the face-to-face meeting in March, 
the Guideline Development Group held subsequent discussions by videoconference on May 31, June 26, 
July 31 and August 28, 2019 to review draft versions of this publication.
Peer review
The draft guidelines were circulated for review to members of the Guideline Development Group and 
the External Review Group. The Guideline Development Group reviewed the comments and incorporated 
them into the final document with due consideration of any conflicts of interest of External Review 
Group members.
Declarations of interest
All external contributors to the guidelines, including members of the Guideline Development Group, 
External Peer Review Group, systematic reviewers and contributors to the supporting evidence 
completed a WHO declaration of interests form in accordance with WHO policy (50). The steering 
committee of the WHO/PAHO Guideline Steering Group collected and reviewed a brief biography of each 
Guideline Development Group member before the first meeting of the Guideline Development Group. 
No objections were received concerning the members of the Guideline Development Group. At the start 
of the guideline development meeting, all conflicts of interest identified and the management plan for 
any conflicts of interest were shared with the meeting participants. Of the members of the Guideline 
Development Group, one received diagnostic kits from commercial companies at no cost (no relation 
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with the diagnostic kits or interventions included in this guideline), one received a research grant to 
conduct clinical trials (no medication or interventions related to the content in this guideline) and two 
had received a grant to attend conferences (by a private company but with no links to any intervention 
included in this guideline). No conflicts of interest warranted exclusion from the discussion of specific 
recommendations. To ensure consistency, the WHO/PAHO Guideline Steering Group applied the criteria 
for assessing the severity of conflict of interests in the WHO handbook for guideline development (50). 
All contributors were requested to promptly notify WHO/PAHO if any of the disclosed information 
changed during the course of this work.
The responsible technical officer reviewed the declaration of interest forms from members of the External 
Review Group in accordance with WHO guideline development policy, and the results were shared with 
the Guideline Steering Group. Any conflicts of interest identified were considered when interpreting 
comments from External Review Group members during the external review process (51).
All declaration of interest forms are in electronic file at the PAHO Communicable Diseases and 
Environmental Determinants of Health Department and will be maintained for 10 years.
Methods for appraising evidence
The Guideline Steering Group formulated PICO (population, intervention, comparison, and outcome) 
questions to guide the systematic reviews used in developing these guidelines (52). The following three 
questions were identified.
• Among people with HIV disease, is antigen testing versus standard microbiological techniques 
of diagnosis associated with an increase in the diagnosis of histoplasmosis and a decrease in 
mortality?
• Among people living with HIV infection with disseminated histoplasmosis, what are the optimal 
therapeutic regimens depending on the disease severity and the level of country resources?
• How does HIV or TB therapy need to be modified to obtain successful outcomes for histoplasmosis 
for people coinfected with TB, HIV, and H. capsulatum?
A list of potential outcomes of interest for each question was circulated to all members of the Guideline 
Development Group, and members provided comments to rank the importance of these outcomes to 
inform decision-making.
Retrieving, summarizing, and presenting the evidence: quantitative evidence synthesis 
and evidence for recommendations
The External Review Group developed protocols for questions 1, 2, and 3 identifying studies, appraising 
the risk of bias, and summarizing the research using standard methods. Annexes 3, 5, and 6 summarize 
these reviews.
To inform the development of these guidelines, evidence was retrieved from three systematic reviews on:
(1) histoplasmosis diagnosis outcomes using antigen testing compared with standard microbiological 
techniques of diagnosis at local and reference hospitals;
(2) efficacy (clinical success and death) and safety (nephrotoxicity and drug discontinuation) of initial 
therapy for severe or moderately severe progressive disseminated histoplasmosis using amphotericin 
B versus alternative antifungal treatments among people living with HIV with moderately severe or 
severe progressive disseminated histoplasmosis in low- and middle-income countries; and
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(3) how HIV or TB therapy needs to be modified to obtain successful outcomes for people coinfected 
with TB, HIV, and Histoplasma capsulatum. 
To examine feasibility and health system considerations, acceptability, financial and economic 
considerations, and human rights and equity issues, structured searches were conducted in PubMed, 
LILACS and Health Systems Evidence (January 2009 to March 1, 2019). The identified studies were 
considered during the GRADE evidence-to-decision framework process.
The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) method was 
used to rate the certainty of the evidence and determine the strength of the recommendations (53). 
The strength of a recommendation reflects the degree to which the Guideline Development Group 
is confident that the desirable effects (potential benefits) of the recommendation outweigh the 
undesirable effects (potential harm). The desirable effects may include beneficial health outcomes 
(such as reduced morbidity and mortality), reduction of the burden on the individual and/or health 
services and potential cost savings. Undesirable effects include those affecting individuals, families, 
communities or health services. Additional considerations include the resource use and cost 
implications of implementing the recommendations and clinical outcomes (such as drug resistance 
and drug toxicity). The Guideline Development Group considered the values and preferences of 
patients, physicians, and decision-makers. The composition of the panel included physicians, laboratory 
specialists, and ministry executives. The perspective of patients and families was represented by a 
Guideline Development Group member who collaborates with a nongovernmental organization that 
defends the views of patients and families to medical institutions. In addition, before the Manaus 
meeting, a systematic search was performed in PubMed including the terms histoplasmosis OR 
histoplasma AND patient preference, OR values, OR choices, OR expectation, OR attitude, OR point of 
view, OR acceptance*, OR user perspective, OR equity, OR human rights. Of 102 references screened, 
11 were retained because they would help to inform the recommendation process.
The strength of a recommendation can be either strong or conditional
A strong recommendation (for or against) is one for which there is confidence that the desirable 
effects of adhering to the recommendation clearly outweigh the undesirable effects.
A conditional recommendation (for or against) is one for which the certainty of the evidence may be 
low or may apply only to specific groups or settings.
The Guideline Development Group formulated recommendations based on the certainty of the 
evidence, the balance between benefits and harm, values and preferences (including patients, health-
care workers, and policymakers), resource implications and acceptability and feasibility. The Guideline 
Development Group assessed these through discussion among the members. The evidence-to-decision 
framework was used to approach each PICO question.
Equity and human rights
Throughout the development of this guideline and the GRADE evidence-to-decision framework 
process, each recommendation was assessed based on how it could potentially affect human rights 
and equity. Overall, the Guideline Development Group was confident that improving access to the 
interventions recommended by these guidelines would not reduce equity or human rights. People 
living with HIV and/or TB from groups that are marginalized or stigmatized have poor access to health 
services. Access to a point-of-care diagnostic test for histoplasmosis can improve the diagnosis and 
management of people with histoplasmosis and contribute to overcoming some of the obstacles to 
access among these populations.
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Regional meeting on histoplasmosis in the Americas
A Regional Meeting of the International Histoplasmosis Advocacy Group (iHAG) was held in Manaus, 
Brazil, on March 22–24, 2019. More than 100 participants from 24 countries (21 from the Americas) 
attended the three-day meeting to discuss surveillance, diagnosis and treatment in Latin America. It 
was reported that 65% of countries had rapid testing for histoplasmosis in at least one laboratory 
for routine diagnosis. More than 90% of countries reported the availability of itraconazole and 
amphotericin B deoxycholate, but access to liposomal amphotericin B was limited (61%). Only two 
countries (Nicaragua and the United States) include histoplasmosis in their surveillance systems, with 
limited reporting in the United States (reportable in fewer than 15 states).
A regional SWOT analysis (strengths, weaknesses, opportunities, and threats) was conducted, focusing 
on three main topics: (1) access to diagnostic tests, with a focus on in vitro tests for rapid diagnosis, 
(2) access to specific antifungal therapy, and (3) surveillance of HIV-associated histoplasmosis 
(focusing on morbidity and mortality) (54). The main challenges and opportunities identified were as 
follows.
Challenges
Diagnosis
• A Histoplasma enzyme immunoassay kit is not registered in most countries.
• A Histoplasma enzyme immunoassay is available in a few scattered and highly specialized 
reference laboratories.
• Point-of-care testing is not commercially available.
• Validation studies outside the context of people with advanced HIV are lacking.
Treatment
• Amphotericin B and itraconazole are licensed but unavailable or not prescribed.
• Evidence of safety and efficacy is limited (few and old clinical trials).
• Clinical trials of alternative antifungal drugs are lacking.
• Evidence is lacking in specific populations (TB, pregnancy, liver or renal diseases, and children).
Surveillance
• Health-care practitioners and public health authorities lack awareness and education.
• Histoplasmosis is not a reportable disease. The burden of disease not fully known.
• Histoplasmosis is not integrated into national or international HIV and TB programs.
Opportunities
Diagnosis
• Histoplasma point-of-care test (lateral flow assay) being developed.
• PAHO/WHO to facilitate registration of new diagnostic kits.
• PAHO/WHO price control and engage industry.
• Development of a laboratory quality assurance program.
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Treatment
• PAHO/WHO price control and engagement of industry.
• PAHO/WHO increasing access to liposomal amphotericin B.
• Collaboration with the pharmaceutical industry to increase access to new antifungal agents and 
management strategies.
Surveillance
• Screening studies in populations with varying risk of histoplasmosis.
• Evaluate how new tests affect incidence and mortality.
• Develop an electronic standard case report system.
• Returning travelers or immigrants from known endemic areas diagnosed in high-income 
countries may help in reporting information from endemic areas.
• Assessment of the environmental risk for histoplasmosis (work, industry, agriculture, and 
tourism).
• Merging with other programs (TB, HIV, and neglected tropical diseases) within the framework of 
the PAHO/WHO strategic plan.
• Develop advocacy, training, and education programs.
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ANNEX 2 . SUMMARY OF JUDGMENTS ON 
POPULATION, INTERVENTION, COMPARISON, 
AND OUTCOME (PICO) QUESTIONS
PICO 1 PICO 2A PICO 2B PICO 2C PICO 3
Problem Favors this option Yes Probably no Yes Yes
Desirable effects Favors this option Moderate Moderate Don’t know Moderate
Undesirable effects Favors this option Trivial Trivial Small Large
Values Favors this option No important 
uncertainty or 
variability
No 
important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Balance of effects Favors this option Probably 
favors the 
intervention
Probably 
favors the 
intervention
Don’t know Probably 
favors the 
intervention
Acceptability Favors this option Yes Yes Probably yes Yes
Feasibility Favors this option Yes Yes Yes Yes
Certainty of the 
evidence
– Low No included 
studies
No included 
studies
Very low
Certainty of the evidence 
of test accuracy
Probably favors 
this option
– – – –
Certainty of the evidence 
of test’s effects
Probably favors 
this option
– – – –
Certainty of the evidence 
of management’s effects
Probably favors 
this option
– – – –
Certainty of the evidence 
of the test result and 
management
Probably favors 
this option
– – – –
Cost-effectiveness Probably favors 
this option
– – – –
Certainty of effects Neither favors 
this or other 
options
– – – –
Test accuracy Favors this option – – – –
–: does not apply; PICO: population, intervention, comparison, and outcome. PICO 1. Among people with HIV disease, is antigen testing versus 
standard microbiological techniques of diagnosis associated with an increase in the diagnosis of histoplasmosis and a decrease in mortality? 
PICO 2A. Does liposomal amphotericin B as initial therapy for severe or moderately severe progressive disseminated histoplasmosis have 
better efficacy and safety than alternative antifungal treatments? PICO 2B. Is there a difference in histoplasmosis relapse rate between less 
than 12 months or more than 12 months of oral antifungal maintenance therapy for progressive disseminated histoplasmosis among people 
living with HIV? PICO 2C. Is early antiretroviral therapy (less than two weeks) preferable to deferred antiretroviral therapy (two weeks or 
more) among people living with HIV who have progressive disseminated histoplasmosis? PICO 3. How does HIV or TB therapy need to be 
modified to obtain successful outcomes for people coinfected with TB, HIV, and H. capsulatum?
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ANNEX 3 . SYSTEMATIC REVIEW PICO 1: 
PERFORMANCE OF DIAGNOSTIC ASSAYS
Objectives
To evaluate the analytical performance of laboratory assays for diagnosing progressive 
disseminated histoplasmosis among people living with HIV.
Methods
Search methods
Databases: Medline (Ovid), Embase (Ovid), CAB Abstracts (Ovid), Global Health (Ovid), Scopus, the 
Cochrane Library, PubMed Central, and LILACS.
Run date: February 20, 2019 for the terms histoplasmosis, HIV, and terms for the diagnostics 
assays evaluated, including their synonyms, in the title, abstract, keywords, or subject headings. 
A broader search was also conducted in the same databases for histoplasmosis and HIV, and a 
diagnostic methods search filter was adapted from the McMaster Health Information Research 
Unit’s recommended search hedges. Searches were limited to the studies published in English, 
Spanish, and Portuguese.
Types of studies: systematic review
Studies related to validating Histoplasma laboratory assays. Studies were excluded if they did 
not focus on human application or were primarily case reports, clinical studies, environmental or 
epidemiological studies, or literature reviews with no validation component.
For studies related to validating laboratory assays for diagnosing histoplasmosis, we excluded 
studies of people without HIV, concordance studies, and studies without a clear number of people 
tested. To maintain the accuracy of the study, references were not included in the analysis if culture 
or histopathological analyses were not included to determine proven cases.
Statistical analysis and data synthesis: meta-analysis
Data from selected studies were extracted to reconstructed 2 by 2 tables. Meta-analysis was 
performed using STATA’s metandi and metan commands. Data were summarized using meta-
analysis forest plot and hierarchical summary receiver operating characteristic (HSROC) curves.
Main results
Histoplasma antigen assays were determined to be the most accurate method for diagnosing 
progressive disseminated histoplasmosis in advanced HIV. Molecular assays appear promising for 
accurately diagnosing histoplasmosis, but consensus on the exact techniques is needed. Cultures 
showed variable sensitivity related to sample type and laboratory handling. Antibody assays 
presented high specificity but low sensitivity (19).
Authors’ conclusions
The results of the meta-analysis showed that laboratory assays based on detecting circulating 
Histoplasma antigen demonstrated the best analytical performance. Since there is very-low-
certainty evidence, we recommend further prospective research.
Analytical performance of assays
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Culture: sensitivity 77% (no data for specificity calculation)
Study summary (reference):
1. Messina F, Argentina, blood culture [lysis centrifugation] (16)
2. Oliveira F, Brazil, blood culture [lysis centrifugation] (17)
3. Unis G, Brazil, conventional fungal media, respiratory samples (18)
4. Bianchi M, Argentina, blood culture [lysis centrifugation] (19)
5. Arechavala A, Argentina, conventional fungal media, multiple type samples (20)
6. Zarabi C, USA, conventional fungal media, multiple type samples (21)*
7. Zarabi C, USA, conventional fungal media, blood (21)*
8. Zarabi C, USA, conventional fungal media, bone marow (21)*
9. Zarabi C, USA, conventional fungal media, tissue (21)*
10. Zarabi C, USA, conventional fungal media, sputum (21)*
11. Zarabi C, USA, conventional fungal media, lower respiratory samples (21)*
12. Zarabi C, USA, conventional fungal media, body fluids (21)*
13. Nightingale S, USA, conventional fungal media, blood (22)*
14. Nightingale S, USA, conventional fungal media, blood + smear (22)*
15. Nightingale S, USA, conventional fungal media, bone marrow (22)*
(*, +) Data extracted from the same study
■ Study weight
◆ Overall 95% confidence interval (95% CI)
Source: Caceres et al. J. Fungi 2019, 5(3), 76 (19).
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Overall
93.00 (77.00, 99.00)
57.00 (34.00, 78.00)
60.00 (26.00, 88.00)
90.00 (81.00, 95.00)
70.00 (54.00, 83.00)
39.00 (22.00, 58.00)
83.00 (36.00, 100.00)
71.00 (29.00, 96.00)
20.00 (1.00, 71.00)
0.00 (0.00, 71.00)
17.00 (0.00, 64.00)
0.00 (0.00, 62.00)
72.00 (53.00, 86.00)
88.00 (69.00, 97.00)
80.00 (44.00, 97.00)
76.71 (72.46, 80.97)
14.94
3.74
1.88
36.89
8.60
5.58
1.77
1.61
1.48
1.43
1.77
1.88
6.64
9.22
2.57
100.00
% weight(A) Sensivity (95% CI)
0     20     40    60     80   100
Figure 1. Meta-analysis of the sensitivity for the culture assay’s analytical performance
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ANNEX 4 . DIAGNOSTIC TESTS FOR 
HISTOPLASMOSIS
Company/product Antigen
IMMY/Clarus Histoplasma GM Enzyme 
Immunoassay (Ref. HGM201)
Commercial: CE label. Detection of antigens in urine.
Research use only in the United States. United States Food 
and Drug Administration clearance underway.  
https://www.immy.com/hgm
MiraVista/Polyclonal Ab ELISA
(CPT code: 87385)
In-house: Indianapolis, IN, USA. Detection of antigens in urine, 
sera, and other body fluids. In the process of commercialization.
https://miravistalabs.com/medical-fungal-infection-testing/
antigen-detection/histoplasma-quantitative-eia-test
Molecular
HOLOGIC/AccuProbe Histoplasma 
capsulatum culture identification test
(Ref. 102910)
In situ hybridization assay for identification of H. capsulatum 
isolated from culture
Culture
Abbott/ISOLATOR™
(Ref. 50C7)
Commercial: Lysis centrifugation system https://www.alere.
com/en/home/product-details/isolator-10ml-microbial-tubes.
html
BD/BACTEC™ Myco/F Lytic (Ref. 442288) Commercial: CE label. Lysis system, automatic incubation system
http://legacy.bd.com/ds/technicalCenter/inserts/PP162JAA(05).pdf 
Antibody
IMMY/Immunodiffusion Fungal Antibody 
Test Kit
(Ref. ID1001)
Commercial: CE label
http://www.immy.com/products/immunodiffusion-reagents-
and-plates/#1473453177095-9d6fbd00-fc50
Meridian/Immunodiffusion reagents
(Ref: 100201 and 100601)
Commercial: approved by the United States Food and Drug 
Administration
https://www.meridianbioscience.com/human-condition/other/
fungals/histoplasma-antigen-for-fungal-immunodiffusion
IMMY/Complement Fixation Reagents
(Ref. H10150, H20110, H30150 and 
H40110)
Commercial: CE and in vitro diagnostic label
http://www.immy.com/complement-fixation-
reagents/#1473453809831-e685dea0-e154
IMMY. LA-Histoplasma  
(Ref. HL1001)
Commercial: approved by the United States Food and Drug 
Administration and CE label. https://www.immy.com/latex
Gibson Bioscience. Fungal serology. Commercial: The ATCC Licensed Derivative Emblem.
http://www.gibsonbioscience.com/GB-Products/Fungal-
Serology/
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ANNEX 5 . SYSTEMATIC REVIEW PICO 2: 
HISTOPLASMOSIS TREATMENT
Abstract
Background
Disseminated histoplasmosis is a serious fungal infection affecting people with advanced HIV. The 
optimal treatment regimens are unclear.
Objectives
Objective 1 – induction: to compare the efficacy and safety of initial therapy with liposomal 
amphotericin B versus initial therapy with alternative antifungal agents.
Objective 2 – maintenance: to compare the efficacy and safety of maintenance therapy with 12 
months of oral antifungal treatment versus shorter durations.
Objective 3 – antiretroviral therapy: to compare the outcomes of early versus delayed initiation of 
antiretroviral therapy.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; Central Register of 
Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (PubMed, from 1966 to 
the present); Embase (OVID, from 1947 to the present); Science Citation Index Expanded (SCI-
EXPANDED, from 1900), Conference Proceedings Citation Index-Science (CPCI-S, from 1900), and 
BIOSIS Previews (from 1926). We also searched the WHO International Clinical Trials Registry 
Platform (http://www.who.int/ictrp/search/en), ClinicalTrials.gov, and the ISRCTN registry (www.
isrctn.com) to identify ongoing studies.
Selection criteria
We evaluated studies assessing the use of liposomal amphotericin B and alternative antifungal 
agents for induction therapy; studies assessing the duration of antifungal agents for maintenance 
therapy; and studies assessing the timing of antiretroviral therapy. We included randomized 
controlled trials, single-arm trials, prospective cohort studies, and single-arm cohort studies.
Data collection and analysis
Two review authors assessed eligibility and the risk of bias, extracted data and assessed the 
certainty of evidence. We used the ROBINS-I tool to assess the risk of bias in non-randomized 
studies. We summarized dichotomous outcomes using relative risks (RR).
Main results
We identified 17 individual studies, 10 of which could inform our review objectives. We found one 
randomized controlled trial that compared liposomal amphotericin B to deoxycholate amphotericin 
B. Compared with deoxycholate amphotericin B, liposomal amphotericin B may have higher clinical 
success rates (RR 1.46, 95% confidence interval (CI) 1.01–2.11, 80 participants, one study, low-
certainty evidence) and lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09–0.67, 77 participants, 
one study, high-certainty evidence) (29).
34
We found very-low-certainty evidence to inform comparisons between amphotericin B formulations 
and azoles for induction therapy.
We found very-low-certainty evidence to inform whether early versus deferred antiretroviral therapy 
is preferable in disseminated histoplasmosis.
Authors’ conclusions
Liposomal amphotericin B appears to be preferable to deoxycholate amphotericin B for treating 
people living with HIV for disseminated histoplasmosis in areas where it is available. Since there is 
very-low-certainty evidence to inform other treatment choices, we recommend further prospective 
research.
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ANNEX 6 . SYSTEMATIC REVIEW PICO 3: 
HISTOPLASMOSIS AND TB COINFECTION
Objectives
To evaluate the safety of available treatment strategies for TB and histoplasmosis coinfection 
among people living with HIV.
The evidence base is limited, and we therefore adapted our objectives to the following:
• to describe recognized drug–drug interactions between first-line therapies for histoplasmosis, 
TB, and HIV; and
• to describe clinical approaches to TB, histoplasmosis, and HIV infection
Methods
Criteria for considering studies for this review
Types of studies
• Randomized controlled trials
• Quasi-randomized controlled trials and non-randomized controlled trials
• Prospective cohort studies, including single-arm cohort studies
• Retrospective cohort studies, including single-arm cohort studies
• Case series
• Case reports
Types of participants
Children, adolescents, and adults living with HIV with coexisting progressive disseminated 
histoplasmosis and TB.
Types of interventions
• Itraconazole with rifampicin-based anti-TB regimen
• Itraconazole with non-rifampicin-based anti-TB regimen
Types of outcome measures
Primary outcomes
• All-cause mortality
• Treatment failure of HIV
• Treatment failure of TB
• Treatment failure of histoplasmosis
Secondary outcomes
• Serious adverse events
• Duration of hospital stay
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Methods
We developed our search strategy with the assistance of Vittoria Lutje, Information Specialist. We 
searched the following: Cochrane Infectious Diseases Group Specialized Register; Central Register 
of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE (PubMed, from 1966 to 
present); EMBASE (OVID, from 1947 to present); Science Citation Index Expanded (SCI-EXPANDED, 
from 1900), Conference Proceedings Citation Index-Science (CPCI-S, from 1900), and BIOSIS 
Previews (from 1926), all three using the Web of Science platform. We also searched the WHO 
International Clinical Trials Registry Platform (http://www.who.int/ictrp/search/en), ClinicalTrials.gov, 
and the ISRCTN registry (www.isrctn.com) to identify ongoing studies.
One reviewer (Marylou Murray) selected studies from the search results and extracted data.
We do not present GRADE evidence profiles, since all the evidence presented is of very low 
certainty due to the design of the contributing studies.
Results
Results of the search
We found only two studies that could directly inform the PICO. In addition, we report anticipated 
drug–drug interactions from established databases, but this does not represent a pharmacokinetic 
review.
Effects of interventions
One retrospective cohort study (41) compared outcomes for different treatment strategies for 
comorbid disseminated histoplasmosis and people with both TB and HIV. The authors do not 
comment on antiretroviral drug choices.
One case report (40) indicated outcomes for a single person treated with rifampicin and 
itraconazole.
One person in ACTG120 receiving rifampicin for Mycobacterium avium-intracellulare – undetectable 
itraconazole levels, died.
These are summarized in the following table:
Study Strategy Number of people Outcomes
Agudelo et 
al. (41)
Itraconazole + 
RHZE
At initiation
n = 10
After switch
n = 7
Loss to follow-up: 1/7
Detectable itraconazole levels: 0/3 
measured
Treatment success: 4/6
Death: 1/6
Relapse (TB + progressive disseminated 
histoplasmosis): 1/6
Itraconazole 
+ quinolone + 
HZE
At initiation
n = 4 
After switch
n = 7
Loss to follow-up: 1/7
Detectable itraconazole levels: 2/2 
measured
Treatment success: 4/5 (one switched from 
RHZE to quinolone HZE because of clinical 
failure) 
Drayton et 
al. (40)
Itraconazole + 
RHZE
1 Undetectable serum itraconazole levels 
during rifampicin administration.
Discontinuation of R led to improvement in 
progressive disseminated histoplasmosis. 
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